EPAC-lung: European pooled analysis of the prognostic value of circulating tumour cells in small cell lung cancer

Foy, Victoria; Lindsay, Colin R.; Carmel, Alexandra; Fernández‐Gutiérrez, Fabiola; Krebs, Matthew; Priest, Lynsey; Carter, Mathew; Groen, Harry J.M.; Hiltermann, T Jeroen N; Luca, Antonella De; Farace, Françoise; Besse, Benjamin; Terstappen, L; Rossi, Elisabetta; Morabito, Alessandro; Perrone, Francesco; Renehan, Andrew G.; Faivre-Finn, Corinne; Normanno, Nicola; Blackhall, Fiona; Michiels, Stefan

doi:10.21037/tlcr-20-1061

Cited by 9 publications

(4 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Recently, a similar study conducted by Foy et al showed that higher pretreatment CTC counts are a negative independent prognostic factor in SCLC when considered as a continuous variable or dichotomised counts of ≥15 or ≥50. 36 Nevertheless, this study only included studies from four European cancer centers and they only investigated the relationship between pretreatment CTCs level and patients’ clinical outcomes. Therefore, we conducted the current meta-analysis to comprehensively investigate the prognostic significance of CTCs in SCLC and provide evidence support to clinical practice.…”

Section: Discussionmentioning

confidence: 99%

Assessment of the Clinical Utility of Circulating Tumor Cells at Different Time Points in Predicting Prognosis of Patients With Small Cell Lung Cancer: A Meta-Analysis

et al. 2021

View full text Add to dashboard Cite

Objectives Numerous studies have elucidated that circulating tumor cells (CTCs) have significant prognostic value in various solid tumors. However, the prognostic value of CTCs in small cell lung cancer (SCLC) remains controversial. The current study was performed to investigate the prognostic significance of different time points of CTCs in SCLC. Methods PubMed, EMBASE, Web of Science, and Cochrane Library databases were retrieved for eligible studies. Pooled hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated to investigate the association between CTCs level and overall survival (OS) and progression-free survival (PFS) in SCLC. Furthermore, subgroup analyses, sensitivity analysis, Begg’s and Egger’s tests were also conducted. Results Sixteen cohort studies with 1103 participants were eligible for this meta-analysis. Our results revealed that higher pretreatment CTCs level was significantly correlated with worse OS in SCLC no matter CellSearch (HR, 2.95; 95%CI, 1.56-5.58; P = .001) or other methods (HR, 2.37; 95%CI, 1.13-4.99; P = .023) was used to detect CTCs. Higher pretreatment CTCs status detected by CellSearch was associated with shorter PFS (HR, 3.75; 95%CI, 2.52-5.57; P < .001), while there was no significant association when other methods were adopted to CTC detection (HR, 2.04; 95%CI, .73-5.68; P = .172). Likewise, we observed that higher post-therapy CTCs level detected by both CellSearch (HR, 2.99; 95%CI, 1.51-5.93; P = .002) and other methods (HR, 4.79; 95%CI, 2.03-11.32; P < .001) was significantly correlated with decreased OS in SCLC. However, higher post-therapy CTCs count detected by CellSearch was not correlated with worse PFS (HR, 1.80; 95%CI, .83-3.90; P = .135). Sensitivity analysis demonstrated that the pooled data were still stable after eliminating studies one by one. However, significant publication bias was observed between pretreatment CTCs level detected by CellSearch and OS of SCLC. Conclusion Dynamic monitoring of CTCs level could be a non-invasive and effective tool to predict the disease progression and prognosis in patients with SCLC.

show abstract

Section: Discussionmentioning

confidence: 99%

Assessment of the Clinical Utility of Circulating Tumor Cells at Different Time Points in Predicting Prognosis of Patients With Small Cell Lung Cancer: A Meta-Analysis

et al. 2021

View full text Add to dashboard Cite

show abstract

“…First, high level of CTCs at baseline is a negative prognostic factor for PFS and OS, as confirmed by a meta-analysis of Zhang and collegues ( 62 ). Secondly, a clear cut-off has not been identified ( 99 ).…”

Section: Methodsmentioning

confidence: 99%

Tissue and circulating biomarkers of benefit to immunotherapy in extensive-stage small cell lung cancer patients

Lorenzi,

Resi,

Bonanno

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

Extensive stage-Small-Cell Lung Cancer (ES-SCLC) is an aggressive cancer with dismal prognosis. The addition of immune-checkpoint inhibitors (ICIs) to platinum-based chemotherapy have been consistently demonstrated to improve outcomes and survival, becoming the new standard in first – line treatment of ES-SCLC patients. However, despite positive results reported in the pivotal trials, longer benefit appears evident only for a selected group of patients. Several predictive biomarkers have been studied so far but the prospective identification of patients more likely to experience better outcome seems to be challenging in SCLC. Indeed, classical immune predictive biomarkers as PD-L1 and tumor mutational burden (TMB) seem not to correlate with outcomes. Recently, a new molecular classification of SCLC based on differential expression of genes associated with specific clinical behaviors and therapeutic vulnerability have been presented suggesting a new field to be investigated. Despite the achievements, these studies focused mainly on inter-tumoral heterogeneity, limiting the exploration of intra-tumoral heterogeneity and cell to cell interactions. New analysis methods are ongoing in order to explore subtypes plasticity. Analysis on single biopsies cannot catch the whole genomic profile and dynamic change of disease over time and during treatment. Moreover, the availability of tissue for translational research is limited due to the low proportion of patients undergoing surgery. In this context, liquid biopsy is a promising tool to detect reliable predictive biomarkers. Here, we reviewed the current available data on predictive role of tissue and liquid biomarkers in ES-SCLC patients receiving ICIs. We assessed latest results in terms of predictive and prognostic value of gene expression profiling in SCLC. Finally, we explored the role of liquid biopsy as a tool to monitor SCLC patients over time.

show abstract

“…Выявление ЦОК не считается оптимальным методом для ранней детекции новообразований, хотя можно заметить, что некоторые разновидности неоплазм отличаются повышенной склонностью диссеминировать ЦОК (например, рак молочной железы, мелкоклеточный рак легкого и т.д.) [115]. Но анализ ЦОК может эффективно дополнять иные разновидности ЖБ [116].…”

Section: ен имянитов еш кулигина га янусunclassified

Liquid Biopsy in Clinical Oncology

Imyanitov¹,

Kuligina²,

Janus³

2022

Practical oncology

View full text Add to dashboard Cite

Liquid biopsy is the analysis of tumor fragments (entire cells, nucleic acids,proteins) in hysiological and pathological body liquids. This technology has already been included in standard procedures of detecting secondary mutations, which are associate with acquired drug resistance. Liquid biopsy is a promising tool for early cancer detection, evaluation of the success of radical cancer surgery, monitoring of residual tumor disease, assessment of treatment efficacy etc.

show abstract

EPAC-lung: European pooled analysis of the prognostic value of circulating tumour cells in small cell lung cancer

Cited by 9 publications

References 48 publications

Assessment of the Clinical Utility of Circulating Tumor Cells at Different Time Points in Predicting Prognosis of Patients With Small Cell Lung Cancer: A Meta-Analysis

Assessment of the Clinical Utility of Circulating Tumor Cells at Different Time Points in Predicting Prognosis of Patients With Small Cell Lung Cancer: A Meta-Analysis

Tissue and circulating biomarkers of benefit to immunotherapy in extensive-stage small cell lung cancer patients

Liquid Biopsy in Clinical Oncology

Contact Info

Product

Resources

About